CN1850201A - Method for preparing external-use Chinese medicine for treating ulcerative stomatitis - Google Patents
Method for preparing external-use Chinese medicine for treating ulcerative stomatitis Download PDFInfo
- Publication number
- CN1850201A CN1850201A CN 200610049718 CN200610049718A CN1850201A CN 1850201 A CN1850201 A CN 1850201A CN 200610049718 CN200610049718 CN 200610049718 CN 200610049718 A CN200610049718 A CN 200610049718A CN 1850201 A CN1850201 A CN 1850201A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine
- administration
- external use
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The present invention discloses a Chinese medicine for external application for effectively curing ulcerative stomatitis. It is formed from medicine tablet, non-woven fabric and PVC backlining. Said medicine tablet is made up by using Chinese medicinal materials of asarum and evodia fruit through a certain preparation process. Said invention also provides its application method.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of preparation method for the treatment of the Chinese medicine medicine for external use of oral ulcer.
Background technology
Oral ulcer, recurrent oral ulceration are modal diseases in the diseases of oral mucosa, the incidence rate height.It is steaming on accumulation of heat in the heart and spleen, the stomach-fire, hyperactivity of fire caused by deficiency of YIN that theory of Chinese medical science is recognized its pathogeny, steam in dispute institute extremely on scorchingly hot.The treatment by Chinese herbs oral ulcer is because of more difficult recurrence in back and toxic and side effects are less and well received.The Chinese medicine that is used for the treatment of oral ulcer at present is mainly decoction, membrane, powder, and weak point is all arranged.The fried trouble of decoction, volume is big, carries and takes inconvenience; Buccal bioadhesive tablet and powder, medicated powder directly are coated with spray or the medicine film is affixed on the oral ulcer place, bitter in the mouth behind the medicine dissolution and fiber crops, and medicine irritation ulcer easily causes pain, in use brings misery to the patient, the while medicine is easily washed away by saliva.Chinese patent literature discloses a kind of " Oral cavity healthy paste ", and usage is a course of treatment for plaster being affixed on the space between the eyebrows took off last 24 hour, reaches good therapeutic effect, but is that image appearance to patient damages outside the deficiency.
Summary of the invention
The objective of the invention is to carry and take inconvenience in order to solve Chinese medicine decoction, Chinese medicine buccal bioadhesive tablet and powder medication process Chinese medicine stimulate ulcer to cause pain, in use bring painful problem for the patient, provide a kind of medication convenient, medicine does not directly contact ulcer surface, and no pain has no side effect, therapeutic effect is good, and can not influence the preparation method of Chinese medicine medicine for external use of the treatment oral ulcer of image appearance.
Technical scheme of the present invention realizes in the following manner:
The step of method is as follows:
1. get Herba Asari, water vapour distillation gets volatile oil, adds the micropowder silica gel mixing of 0.5～2.5 times of amount of volatile oil volume, crosses 60～200 mesh sieves, and it is standby to make volatile oil micropowder silica gel mixture;
2. get Fructus Evodiae, add 40～90% ethanol extractions, filter while hot, decompression filtrate recycling ethanol is condensed into thick paste, and drying under reduced pressure was pulverized 60～200 mesh sieves, made the Fructus Evodiae extract powder, and was standby;
3. get substrate, after the heating in water bath fusion, be cooled to 45～65 ℃, insulation adds Fructus Evodiae extract powder, volatile oil micropowder silica gel mixture, stirs, (die throat diameter 13～17mm in the impouring mould, high by 2.0～3.5mm), cooling, the demoulding, get tablet, tablet is put in the PVC nib of foaming, be covered with non-woven rubberized fabric, get product.
Described Herba Asari: Fructus Evodiae=1～10: 1～10.Herba Asari, Fructus Evodiae weight and substrate weight ratio are 1: 0.2～1.Substrate is Polyethylene Glycol.
Good effect of the present invention is:
1. medication is convenient, and therapeutic effect is good; Medication process Chinese medicine external used medicine does not directly contact ulcer surface, no pain; Be difficult for being washed away by saliva; Do not influence image appearance.
2. the transdermal test in vitro test shows that this product Chinese medicine can be stablized release in 24 hours, and duration of efficacy is long.
The specific embodiment:
The invention will be further described below in conjunction with embodiment:
Foundation of the present invention is: the main effective ingredient of Herba Asari is a volatile oil, has effects such as analgesia, antiinflammatory.The main effective ingredient of Fructus Evodiae is alkaloids compositions such as rutaecarpin, rutaecarpine, has effects such as antalgic and inflammation relieving, antiulcer.Molecular weight according to above-mentioned two effective constituents is less, fat-soluble stronger, the transdermal test in vitro test shows that skin is had permeability preferably, be fit to make the characteristics of transdermal absorption formulation, use modern extract refining and transdermal drag delivery, we are made the Chinese medicine medicine for external use that supplies umbilical region administration.Umbilicus (SHENQUE acupoint) is the remittance sea through gas, links to each other with the twelve regular channels, communicates with the vital organs of the human body.Dissect from modern medicine, umbilicus (SHENQUE acupoint) horny layer is thin, no subcutaneous fat, and fascia directly links to each other with peritoneum, the easy Transdermal absorption of medicine.In SHENQUE acupoint, through the infiltration and the defeated cloth of meridians, in penetrating with, the usefulness of performance medicine " return through " makes it to reach in the internal organs meridians by drug effect, and the sick institute of imbalance of YIN and YANG reaches the purpose of healing of canker sores.
The present invention has wind-dispelling heat-dissipating, and the effect of reducing swelling and alleviating pain is used for the treatment of card and belongs to the taste intrinsic heat, oral ulcer, recurrent oral ulceration due to heart-fire, the hyperactivity of deficient fire.Using method is external.Clean umbilical part (SHENQUE acupoint) surrounding skin, dry, then non-woven rubberized fabric is separated with the PVC sheet, tablet is aimed at umbilical part, paste firmly; An a slice, once-a-day.
The pharmacological action of this Chinese medicine medicine for external use:
This Chinese medicine medicine for external use of making a summary has significant therapeutical effect to the oral ulcer by the rabbit of acetic-acid induced; Significantly the pain response time appears in the mouse writhing number of times due to the minimizing glacial acetic acid, prolongation hot plate induced mice; Can significantly reduce by mice auricle swelling rate scorching due to the dimethylbenzene.
Results of pharmacodynamic test:
1, this Chinese medicine medicine for external use is to the therapeutical effect of tentative rabbit oral ulcer
Adopt acetic-acid induced rabbit oral ulcer model, the high, medium and low dosage of coating Chinese medicine medicine for external use is respectively 1.0,0.5,0.25g crude drug/kg, and the positive controls detoxicating tablet of cow-bezoar is irritated stomach; dosage 0.25g/kg; 4g/ of excipient matched group coating excipient, once a day, continuous six days.Before administration and after the experiment end, measure the oral ulcer area respectively, and observe the inflammatory congestion situation, define the level by following standard: 0 grade: do not have blush, no edema around the ulcer; 1 grade: blush, no edema are arranged around the ulcer slightly; 2 grades: blush, no edema are arranged around the ulcer; 3 grades: blush is arranged around the ulcer, edema is arranged, data see Table 1, table 2.
The influence of rabbit oral ulcer area due to the table 1 Chinese medicine medicine for external use Dichlorodiphenyl Acetate
| Group | Dosage (g/kg) | Number of animals (only) | Ulcer area (mm 2) | |
| Before the administration | After the administration | |||
| Dosage group Chinese medicine medicine for external use high dose group in the excipient matched group detoxicating tablet of cow-bezoar group Chinese medicine medicine for external use low dose group Chinese medicine medicine for external use | 0 0.25 0.25 0.5 1.0 | 8 8 8 8 8 | 28.7±2.1 28.7±2.2 28.5±2.1 29.1±2.2 29.1±1.9 | 15.7±4.6 8.9±3.4** 12.7±3.0 10.6±2.1* 5.6±2.6*** |
Compare with the excipient matched group: *: P＜0.05, * *: P＜0.01, * * *: P＜0.001.
The influence of rabbit oral ulcer inflammatory congestion due to the table 2 Chinese medicine medicine for external use Dichlorodiphenyl Acetate
| Group | Dosage (g/kg) | Number of animals (only) | Before the administration (level) | After the administration (level) | ||||||
| 3 | 2 | 1 | 0 | 3 | 2 | 1 | 0 | |||
| Dosage group Chinese medicine medicine for external use high dose group in the excipient matched group detoxicating tablet of cow-bezoar group Chinese medicine medicine for external use low dose group Chinese medicine medicine for external use | 0 0.25 0.25 0.5 1.0 | 8 8 8 8 8 | 8 8 8 8 8 | 0 0 0 0 0 | 0 0 0 0 0 | 0 0 0 0 0 | 4 0 2 0 0 | 3 1 4 2 0 | 1 2 2 4 4 | 0 5** 0 2* 4** |
Compare with the excipient matched group: *: P＜0.05, * *: P＜0.01.
The result: this Chinese medicine medicine for external use dosage has remarkable therapeutical effect greater than rabbit stomatocace due to 0.5g crude drug/kg Dichlorodiphenyl Acetate.
2, this Chinese medicine medicine for external use is studied the mice analgesic activity
2.1 the influence of this Chinese medicine medicine for external use Dichlorodiphenyl Acetate inducing mouse writhing response
Cause the mice pain model with acetic acid, apply that the high, medium and low dosage of this Chinese medicine medicine for external use is respectively 20,10,5g crude drug/kg, the positive controls aspirin is irritated stomach, dosage 200mg/kg, 0.5g/ of excipient matched group coating excipient, once a day, continuous six days.Behind last administration 1h, lumbar injection 0.6% glacial acetic acid 0.2ml/10g, that respectively organizes mice behind the record injection glacial acetic acid in the 20min turns round the body number of times, and data see Table 3.
Table 3 Chinese medicine medicine for external use Dichlorodiphenyl Acetate induced mice is turned round the influence of body number of times
| Group | Dosage (g/kg) | Number of animals (only) | Turn round the body number of times |
| Dosage group Chinese medicine medicine for external use high dose group in the excipient matched group aspirin group Chinese medicine medicine for external use low dose group Chinese medicine medicine for external use | 0 0.2 5.0 10.0 20.0 | 10 10 10 10 10 | 42.8±11.2 16.6±8.9*** 25.8±6.0*** 28.2±7.7** 20.5±10.4*** |
Compare with the excipient matched group: * *: P＜0.01, * * *: P＜0.001.
The result: this Chinese medicine medicine for external use dosage can significantly reduce mouse writhing number of times due to the glacial acetic acid greater than 5.0g crude drug/kg.
2.2 this Chinese medicine medicine for external use causes the influence in pain response time to thermostimulation
Adopt the mice hot plate method, apply that the high, medium and low dosage of this Chinese medicine medicine for external use is respectively 20,10,5g crude drug/kg, the positive controls aspirin is irritated stomach, dosage 200mg/kg, excipient matched group coating excipient 0.5g/ only, once a day, continuous six days.Carry out the test of mice hot plate method behind last administration 1h, data see Table 4.
The influence in pain response time appears in table 4 Chinese medicine medicine for external use to the mice hot plate
| Group | Dosage (g/kg) | Number of animals (only) | The pain response time (second) appears |
| The excipient matched group | 0 | 10 | 12.2±3.7 |
| Dosage group Chinese medicine medicine for external use high dose group in the aspirin group Chinese medicine medicine for external use low dose group Chinese medicine medicine for external use | 0.2 5.0 10.0 20.0 | 10 10 10 10 | 32.0±7.0*** 15.0±3.7 19.0±8.7* 19.2±5.2** |
Compare with the excipient matched group: * *: P＜0.01, *: P＜0.05.
The result: this Chinese medicine medicine for external use dosage can significant prolongation hot plate induced mice the pain response time occur greater than 10.0g crude drug/kg.
3. this Chinese medicine medicine for external use antiinflammatory action
This Chinese medicine medicine for external use is to the antiinflammatory action of mouse ear caused by dimethylbenzene xylene inflammation
Adopt mice caused by dimethylbenzene xylene auricle edema model, apply that the high, medium and low dosage of this Chinese medicine medicine for external use is respectively 20,10,5g crude drug/kg, the positive controls aspirin is irritated stomach, dosage 200mg/kg, 0.5g/ of excipient matched group coating excipient, once a day, continuous six days.Behind last administration 1h, carry out the scorching test of mouse ear caused by dimethylbenzene xylene, data see Table 5.
The influence of table 5 Chinese medicine medicine for external use xylol induced mice auricle edema
| Group | Dosage (g/kg) | Number of animals (only) | Swelling degree (mg) | Inflammation weightening finish percentage rate (%) |
| Dosage group Chinese medicine medicine for external use high dose group in the excipient matched group aspirin group Chinese medicine medicine for external use low dose group Chinese medicine medicine for external use | 0 0.2 5.0 10.0 20.0 | 10 10 10 10 10 | 10.8±3.5 3.1±2.4*** 6.7±4.2* 6.2±3.0** 3.9±2.9*** | 120.7±32.2 33.9±27.4*** 74.1±42.2* 72.7±34.2** 45.9±38.0*** |
Compare with the excipient matched group: *: P＜0.05, * *: P＜0.01, * * *: P＜0.001.
The result: this Chinese medicine medicine for external use dosage can significantly reduce dimethylbenzene induced mice auricle swelling degree and corresponding inflammation weightening finish percentage rate greater than 5.0g crude drug/kg.
The toxicology test result:
1. acute toxicity test
Give skin complete and skin injury (the depilation back with slight oozing of blood degree of being, is caused skin injury with the rubber skin that rubs) rabbit, coating Chinese medicine medicine for external use 30g crude drug/kg, continuous 3 times, each 4 hours at interval, accumulated dose was 90.0g crude drug/kg.Remove medicine with warm water in coating first after 24 hours, observe every day, continuous 14 days.Result: relatively do not have significant difference before the index of reflection whole body poisoning symptoms such as the body weight of two groups of rabbit, skin, hair, eyes, activity, breathing, muscular tension, feces situation and the administration, there is no the overt toxicity reaction, none animal dead.
2. long term toxicity test
(the depilation back is with the rubber skin that rubs to give skin complete and skin injury, with slight oozing of blood degree of being, cause skin injury) rabbit, coating Chinese medicine medicine for external use, twice on the one, high and low dose is respectively 40.0,4.0g crude drug/kg/ days, blank substrate matched group, give skin complete and skin injury (the depilation back with slight oozing of blood degree of being, is caused skin injury with the rubber skin that rubs) the blank substrate of rabbit coating equivalent 6.67g/kg/ days, removed medicine or blank substrate with warm water in 4 hours behind the coating, observe every day, successive administration 28 days, drug withdrawal 14 days is as convalescent period.The result is as follows for the every observation of administration phase and convalescent period, detection index gained:
| Index | Time | The damaged skin group | The intact skin group | ||||
| Contrast | 4.0g/kg | 40.0g/kg | Contrast | 4.0g/kg | 40.0g/kg | ||
| WBC (10 9/L) | Administration drug withdrawal in 28 days is 14 days before the administration | 5.4±1.36 5.7±1.20 6.2±0.49 | 6.1±1.25 6.4±2.36 6.9±1.77 | 6.4±1.58 7.2±2.47 7.0±0.71 | 6.0±2.07 7.4±1.81 6.4±0.64 | 6.8±1.27 6.0±1.08 6.5±0.42 | 7.2±1.79 7.6±1.98 6.7±0.85 |
| LY (％) | Administration drug withdrawal in 28 days is 14 days before the administration | 45.5±6.91 46.4±9.56 47.7±13.04 | 47.3±7.67 47.4±12.59 52.7±1.22 | 47.9±5.76 38.3±13.13 51.4±0.87 | 43.1±10.48 43.2±9.40 50.1±6.12 | 43.1±9.90 48.2±11.28 49.3±3.22 | 41.1±8.83 36.7±6.53 53.4±5.91 |
| MID (％) | Administration drug withdrawal in 28 days is 14 days before the administration | 12.5±4.43 16.9±3.56 13.9±2.27 | 12.8±7.91 16.2±4.60 10.0±1.54 | 13.7±3.97 17.1±5.42 9.7±5.08 | 12.4±3.22 13.0±6.26 13.5±2.47 | 15.4±4.78 17.1±4.58 10.1±3.92 | 16.0±5.51 18.3±7.02 8.3±2.11 |
| GRAN (％) | Administration drug withdrawal in 28 days is 14 days before the administration | 42.0±7.74 36.7±8.31 38.4±15.31 | 40.0±10.22 36.4±13.58 37.3±0.33 | 38.4±7.94 44.6±17.40 38.9±5.95 | 44.4±8.92 43.8±10.32 36.4±3.65 | 41.6±7.94 34.7±10.68 40.5±7.14 | 42.9±9.82 45.0±10.59 38.3±3.80 |
| RBC (10 9/L) | Administration drug withdrawal in 28 days is 14 days before the administration | 4.8±0.85 5.2±0.59 5.5±0.15 | 4.7±0.52 4.9±0.33 5.4±0.16 | 5.5±1.61 5.2±0.65 5.4±1.18 | 5.4±0.57 5.7±0.69 6.0±0.26 | 5.4±0.57 5.1±0.57 5.5±0.32 | 5.0±1.25 5.0±0.92 5.8±0.45 |
| HGB (g/L) | Administration drug withdrawal in 28 days is 14 days before the administration | 99±14.6 107±13.6 98±9.9 | 102±10.8 103±8.8 103±8.5 | 108±30.1 103±14.1 103.5±3.5 | 108±9.9 113±8.1 118.5±7.8 | 111±9.7 106±11.2 107.5±6.4 | 106±22.6 105±17.9 119.5±6.4 |
| HCT (％) | Administration drug withdrawal in 28 days is 14 days before the administration | 30.3±4.91 31.9±4.00 32.1±6.08 | 30.8±3.61 30.8±2.67 32.7±2.12 | 33.2±9.40 30.8±4.22 33.0±5.02 | 33.1±3.46 34.2±2.84 33.7±2.83 | 34.0±3.04 31.7±3.05 30.8±1.91 | 32.5±7.33 31.7±5.63 33.9±2.47 |
| MCV (fL) | Administration drug withdrawal in 28 days is 14 days before the administration | 63.0±3.59 61.2±2.61 62.5±3.89 | 65.2±2.78 63.2±1.90 62.2±0.49 | 61.6±3.10 59.1±2.83 60.3±2.40 | 62.5±1.84 61.1±2.18 61.0±2.05 | 62.1±2.59 62.7±2.86 63.2±2.33 | 63.7±2.44 63.0±2.78 61.4±1.41 |
| MCH (pg) | Administration drug withdrawal in 28 days is 14 days before the administration | 20.6±1.25 20.5±1.02 21.4±0.99 | 21.5±0.74 21.1±0.64 20.2±0.99 | 19.9±1.12 19.7±1.25 21.4±1.48 | 19.8±1.18 19.8±1.25 21.0±1.63 | 20.7±1.16 20.9±1.22 21.3±0.64 | 21.0±1.51 20.8±1.28 21.6±1.20 |
| MCHC (g/L) | Administration drug withdrawal in 28 days is 14 days before the administration | 327±6.7 336±4.0 337±12.0 | 330±8.1 335±3.0 332±14.9 | 326±11.1 333±8.4 331±16.3 | 325±7.6 331±7.4 314±7.1 | 327±5.0 335±8.8 318±4.2 | 327±9.9 331±9.1 315±12.7 |
| RDW-C V(％) | Administration drug withdrawal in 28 days is 14 days before the administration | 15.3±0.9 14.6±1.1 13.9±0.5 | 14.7±1.0 14.3±0.6 13.1±0.6 | 15.6±1.0 15.1±1.1 13.9±1.3 | 15.8±0.7 15.0±0.6 14.5±1.1 | 15.2±0.8 14.7±0.5 14.8±0.9 | 15.3±0.4 14.6±0.9 15.2±0.9 |
(1) 6 treated animals of being tested do not have death in administration phase and convalescent period.
(2) all no abnormal variation of each the dosage treated animal activity in convalescent period, hair color, food-intake after administration phase and drug withdrawal.
(3) body weight change: each dosage treated animal is steady in administration phase and drug withdrawal convalescent period body weight gain, compares no significant difference with blank matrix group, and data see Table 7.
Table 7 Chinese medicine medicine for external use rabbit skin long term toxicity test body weight change (kg, x ± SD)
| Sex | Time | The damaged skin group | The intact skin group | ||||
| Contrast | 4.0g/kg | 40.0g/kg | Contrast | 4.0g/kg | 40.0g/kg | ||
| Female | Drug withdrawal in the 21st day the 28th day in the 14th day in the 7th day in the 0th day drug withdrawal in 7 days 14 days | 1.95±0.13 1.94±0.11 2.01±0.15 2.03±0.15 2.01±0.13 2.12 2.19 | 2.05±0.10 2.08±0.09 2.11±0.08 2.18±0.05 2.15±0.09 2.3 2.33 | 1.94±0.07 1.88±0.07 1.93±0.07 1.94±0.10 1.95±0.12 2.2 2.26 | 2.02±0.08 2.03±0.09 2.11±0.09 2.21±0.09 2.25±0.08 2.21 2.26 | 2.06±0.06 2.08±0.08 2.18±0.08 2.19±0.15 2.18±0.13 2.28 2.35 | 2.15±0.12 2.13±0.16 2.15±0.12 2.16±0.14 2.19±0.10 2.06 2.16 |
| Male | Drug withdrawal in the 21st day the 28th day in the 14th day in the 7th day in the 0th day drug withdrawal in 7 days 14 days | 2.01±0.04 2.08±0.03 2.14±0.04 2.22±0.04 2.28±0.06 2.26 2.33 | 2.09±0.08 2.12±0.11 2.15±0.06 2.22±0.05 2.28±0.06 2.32 2.4 | 2.18±0.10 2.24±0.10 2.21±0.10 2.25±0.25 2.25±0.01 2.31 2.34 | 2.04±0.09 2.07±0.11 2.12±0.05 2.20±0.03 2.23±0.07 2.3 2.39 | 2.04±0.07 2.05±0.09 2.12±0.05 2.23±0.05 2.26±0.05 2.28 2.34 | 2.15±0.10 2.12±0.07 2.08±0.14 2.11±0.09 2.14±0.12 2.36 2.41 |
Annotate: the 0th day～28 days number of animals n of administration are respectively each 4 of male and female, and drug withdrawal convalescent period n is respectively each 1 of male and female.
(4) hematological indices: index such as leukocyte count and classification after 14 days, erythrocyte, platelet count, clotting time all fluctuates in normal range after each dosage group medication 28 days and the drug withdrawal, with before the medication or with blank substrate matched group identical administration phase no significant difference (P＞0.05) relatively, data see Table 8.
Table 8 Chinese medicine medicine for external use rabbit skin long term toxicity test hematological indices (x ± SD)
Annotate: 1. every hematological indices all fluctuates in normal range after the administration;
2. the 0th day～28 days number of animals n of administration are respectively 8, and drug withdrawal convalescent period number of animals n is 2.
(continuous table 8)
| Index | Time | The damaged skin group | The intact skin group | ||||
| Contrast | 4.0g/kg | 40.0g/kg | Contrast | 4.0g/kg | 40.0g/kg | ||
| RDW-SD (fL) | Administration drug withdrawal in 28 days is 14 days before the administration | 35.7±1.5 33.6±1.6 33.8±0.6 | 35.4±2.5 33.9±1.5 32.5±1.3 | 35.0±1.8 34.1±1.7 32.1±0.9 | 35.4±2.0 34.2±1.7 32.1±0.9 | 36.0±2.4 34.0±1.3 34.2±1.5 | 36.6±1.8 34.4±1.3 33.6±1.1 |
| PLT (10 9/L) | Administration drug withdrawal in 28 days is 14 days before the administration | 295±83.1 250±64.5 317±58.0 | 281±78.9 238±67.9 261±25.0 | 290±107.4 267±58.6 280±49.0 | 290±87.1 283±40.9 282±47.0 | 300±89.3 276±72.2 275±25.0 | 348±120.1 311±118.4 299±32.0 |
| MPV(fL) | Administration drug withdrawal in 28 days is 14 days before the administration | 9.8±1.19 10.5±0.84 10.6±1.60 | 9.1±1.21 9.6±0.93 10.2±0.50 | 10.3±1.19 10.5±1.19 10.5±3.30 | 11.0±0.99 10.5±0.93 10.3±0.60 | 10.0±1.19 9.9±1.16 9.9±0.30 | 9.5±2.03 9.8±1.45 11.2±0.80 |
| PDW | Administration drug withdrawal in 28 days is 14 days before the administration | 18.4±0.8 19.7±0.5 18.7±0.3 | 18.1±0.5 19.0±0.6 17.7±1.3 | 18.4±1.1 18.9±1.0 18.1±0.4 | 18.6±0.8 19.2±1.0 19.85±0.5 | 18.5±0.6 19.0±0.8 19.6±1.1 | 18.0±0.7 19.0±0.6 19.4±1.3 |
| PCT (％) | Administration drug withdrawal in 28 days is 14 days before the administration | 0.318±0.119 0.264±0077 0.245±0.058 | 0.251±0.063 0.217±0.045 0.223±0.052 | 0.312±0.129 0.279±0.068 0.284±0.031 | 0.322±0.121 0.300±0.056 0.318±0.008 | 0.350±0.123 0.273±0.079 0.275±0.011 | 0.330±0.138 0.281±0.100 0.299±0.018 |
| Clotting time (second) | Administration drug withdrawal in 28 days is 14 days before the administration | 9.5±42 10.7±3.2 8.7±2.1 | 9.7±3.2 11.1±2.5 9.8±0.9 | 9.6±4.2 9.8±2.4 9.7±0.7 | 9.2±2.3 9.0±1.2 8.4±1.6 | 9.1±3.4 9.6±2.5 10.8±0.6 | 8.9±1.1 8.9±2.9 9.6±3.4 |
Annotate: 1. every hematological indices all fluctuates in normal range after the administration;
2. the 0th day～28 days number of animals n of administration are respectively 8, and drug withdrawal convalescent period n is 2.
(5) blood biochemical is learned: comprise indexs such as ALT, AST, TBIL, TP, ALB, GLB, ALP, CHO, BUN, CR, GLU, CK, TG, each treated animal before medication phase and convalescent period and administration or with the blank substrate matched group same period of no significant difference (P＞0.05) relatively, and in fluctuation normal range, data see Table 9.
Table 9 Chinese medicine medicine for external use rabbit skin long term toxicity test changes of biochemical indexes (x ± SD)
| Index | Time | The damaged skin group | The intact skin group | ||||
| Contrast | 4.0g/kg | 40.0g/kg | Contrast | 4.0g/kg | 40.0g/kg | ||
| ALP (U/L) | Administration drug withdrawal in 28 days is 14 days before the administration | 138±54.2 134±46.8 125±14.1 | 126±61.3 131±39.0 113±9.2 | 133±35.1 95±25.4 113±15.6 | 148±54.5 133±44.4 117±10.6 | 131±41.0 125±44.4 107±12.0 | 119±57.4 98±34.1 107±10.6 |
| ALT (U/L) | Administration drug withdrawal in 28 days is 14 days before the administration | 70±25.7 68±18.3 75±0.7 | 67±21.8 87±27.5 74±17.0 | 67±28.3 86±33.3 71±4.2 | 63±13.4 67±33.7 66±2.1 | 80±42.4 75±29.2 69±4.9 | 63±23.7 87±33.7 74±2.1 |
| AST (U/L) | Administration drug withdrawal in 28 days is 14 days before the administration | 88±16.2 73±16.7 81±4.2 | 84±20.3 93±31.9 77.0±2.8 | 91±9.2 91±21.6 82.0±1.4 | 919±17.7 89.3±17.0 73.0±7.1 | 85±19.6 92±27.8 80.0±11.3 | 88±18.2 89±41.1 84.0±2.8 |
| Alb (g/L) | Administration drug withdrawal in 28 days is 14 days before the administration | 39.8±2.28 38.2±2.70 37.4±1.77 | 39.8±1.88 39.8±1.92 41.4±1.06 | 40.0±1.06 39.5±3.54 35.6±9.97 | 40.3±1.37 38.5±1.91 36.8±1.27 | 39.3±3.75 39.7±2.27 41.3±2.55 | 39.3±1.41 38.1±2.82 38.1±0.21 |
| BUN (mmol/L) | Administration drug withdrawal in 28 days is 14 days before the administration | 6.42±0.59 6.55±0.94 6.69±0.28 | 7.44±1.13 6.97±1.19 5.62±0.83 | 6.47±1.09 8.48±3.97 6.91±0.22 | 6.80±0.95 6.60±1.03 6.74±0.74 | 6.85±1.21 7.94±1.82 7.23±0.04 | 6.96±0.69 7.28±0.61 6.92±0.46 |
| CK (U/L) | Administration drug withdrawal in 28 days is 14 days before the administration | 534±95 529±104 556±97 | 491±95 510±101 513±40 | 501±148 518±126 500±87 | 469±160 508±120 549±47 | 526±153 514±121 505±174 | 500±131 518±128 538±26 |
| Cr (umol/L) | Administration drug withdrawal in 28 days is 14 days before the administration | 78±13 78±13 85±4 | 80±11 81±14 83±9 | 77±13 72±12 84±3 | 82±11 85±18 84±4 | 81±18 83±13 80±2 | 79±9 74±9 83±5 |
| Glu (IU/L) | Administration drug withdrawal in 28 days is 14 days before the administration | 4.81±0.95 4.10±1.22 4.13±0.62 | 4.31±1.29 3.78±0.72 3.84±0.35 | 4.24±1.16 2.84±1.17 3.76±0.42 | 4.01±0.85 3.33±1.50 3.88±0.40 | 3.81±1.84 3.20±1.55 3.40±0.16 | 4.17±0.93 3.02±1.19 3.89±0.38 |
| TB (umol/L) | Administration drug withdrawal in 28 days is 14 days before the administration | 1.25±0.46 1.13±0.35 1.00±0.00 | 1.13±0.35 1.00±0.00 1.00±0.00 | 1.00±0.00 1.63±0.52 1.00±0.00 | 1.25±0.46 1.25±0.46 1.50±0.71 | 1.13±0.35 1.25±0.71 1.00±0.00 | 1.13±0.35 1.38±0.52 1.50±0.71 |
| TG (mmol/L) | Administration drug withdrawal in 28 days is 14 days before the administration | 0.91±0.29 0.80±019 0.94±0.06 | 1.00±0.53 0.97±0.47 1.08±0.69 | 1.05±0.38 0.99±0.39 0.94±0.25 | 0.70±0.21 0.82±0.12 0.93±0.06 | 0.71±0.21 0.94±0.26 0.83±0.05 | 0.77±0.20 0.96±0.26 1.20±0.01 |
| TP (g/L) | Administration drug withdrawal in 28 days is 14 days before the administration | 67.6±5.04 63.7±5.58 63.6±2.40 | 69.1±5.43 65.8±4.84 66.5±0.28 | 67.9±3.84 69.0±6.18 62.2±15.0 | 69.2±9.37 65.9±6.53 61.9±3.61 | 68.6±4.51 68.1±5.02 70.5±0.78 | 70.0±4.04 72.0±4.31 62.1±2.12 |
| Tch (mmol/L) | Administration drug withdrawal in 28 days is 14 days before the administration | 1.24±0.28 1.31±0.16 1.32±0.04 | 1.09±0.30 1.49±0.25 1.62±0.47 | 1.40±0.33 1.66±0.76 1.69±0.24 | 1.06±0.31 1.50±0.31 1.57±0.41 | 1.30±0.26 1.82±0.47 1.60±0.03 | 1.32±0.35 1.78±0.54 1.89±0.62 |
Annotate: 1. every biochemical indexes all fluctuates in normal range after the administration;
2. the 0th day～28 days animal n numbers of administration are 8, and drug withdrawal convalescent period n is 2.
(6) organ coefficient: administration is after 28 days, and numerical value is all approaching between each group of organ coefficient, does not relatively have significant difference with blank substrate matched group.
(7) histopathological examination: perusal and check pathological section show, administration after 28 days internal organs such as each dosage group man Cor Leporis, lung, liver,spleen,kidney, brain, hypophysis cerebri, thyroid, adrenal gland, thymus, stomach, duodenum, bladder, testis, ovary, epididymis, uterus, breastbone, skin there is no unusually.
The result shows that damaged skin and the continuous skin of intact skin rabbit give Chinese medicine medicine for external use 40.0g crude drug/kg and 4.0g crude drug/kg did not have overt toxicity to rabbit in 28 days.
The test of 3 skin irritations
3.1 the skin irritation of single-dose test
Rabbit skin pretreatment: lost hair or feathers the about 150cm of depilation scope with 8% sodium sulfide in the spinal column both sides in preceding 24 hours in test
2/ only (be equivalent to approximately body surface area 10%).Reuse rubber friction skin after wherein damaged skin group rabbit loses hair or feathers is with slight oozing of blood degree of being.Give back rabbit left side depilation district's skin (complete or damaged) coating Chinese medicine medicine for external use 6.0g crude drug/kg, the right side is coated with blank substrate 6.0g/kg, remove medicine and blank substrate with warm water in coating after 6 hours, observe the reaction that 1h, 24h, 48h and 72h smear the position then respectively.Standards of grading see Table 10, table 11.The result: each skin of organizing rabbit does not all have erythema, edema phenomenon (score value is 0), and hair, outward appearance, activity, food-intake, eyes are also all no abnormal.Single is given Chinese medicine medicine for external use 6.0g/kg to rabbit intact skin and the equal nonirritant of damaged skin.
The skin irritation test standard of table 10 rabbit
| The local excitation reaction | Score value |
| Erythema forms: the visible reluctantly obviously visible serious erythema aubergine erythema of no erythema also has eschar to form | 0 1 2 3 4 |
| Edema forms: the visible reluctantly about 1mm of (edge exceeds surrounding skin) cutaneous protuberance of no edema, profile is known the above expanded range of cutaneous protuberance 1mm | 0 1 2 3 4 |
| The highest total mark | 8 |
Table 11 skin irritation intensity evaluation standard
| Mean scores | Estimate |
| 0～0.49 0.5～2.99 3.0～5.99 6.0～8.00 | Nonirritant is slight zest moderate zest strong and stimulating |
3.2 the skin irritation of multiple dosing test
Rabbit skin pretreatment: lost hair or feathers the about 150cm of depilation scope with 8% sodium sulfide in the spinal column both sides in preceding 24 hours in test
2/ only (be equivalent to approximately body surface area 10%).Give back rabbit left side depilation district's skin (complete or damaged) coating Chinese medicine medicine for external use 6.0g crude drug/kg, the right side is coated with blank substrate 6.0g/kg, the damaged skin method for making for the depilation back with the rubber skin that rubs, with slight oozing of blood degree of being, cause skin injury.Every day, coating was 1 time, continuous 7 days, observed 3 days after the drug withdrawal.Standards of grading see Table 10, table 11.The result: the skin irritation test mean scores of complete sum damaged skin administration group rabbit is 0.17, less than slight zest evaluation criterion value 0.5, so think that Chinese medicine medicine for external use multiple dosing does not all have obvious irritation to intact skin and damaged skin.
Embodiment 1:
1, get Herba Asari 580g, add 8 times of water gagings and soaked 1 hour, water vapour distillation 3 hours gets volatile oil, adds the micropowder silica gel mixing of 1 times of amount of volatile oil volume, crosses 100 mesh sieves, and is standby.
2, get Fructus Evodiae 580g, add 80% ethanol extraction 2 times, each 2 hours, filter while hot, decompression filtrate recycling ethanol is condensed into thick paste, and drying under reduced pressure was pulverized 100 mesh sieves, and was standby.
3, taking polyethylene glycol 374.6g after the heating in water bath fusion, is cooled to 50～55 ℃, insulation adds Fructus Evodiae extract powder, volatile oil micropowder silica gel mixture, stirs, (die throat diameter 15mm in the impouring mould, high 2.5mm), cooling, the demoulding, get tablet, tablet is put in the PVC nib of foaming, be covered with non-woven rubberized fabric, get product.
Embodiment 2:
1, get Herba Asari 870g, add 8 times of water gagings and soaked 1 hour, water vapour distillation 3 hours gets volatile oil, adds the micropowder silica gel mixing of 2.0 times of amounts of volatile oil volume, crosses 120 mesh sieves, and is standby.
2, get Fructus Evodiae 290g, add 70%7 alcohol extractions 2 times, each 2 hours, filter while hot, decompression filtrate recycling ethanol is condensed into thick paste, and drying under reduced pressure was pulverized 120 mesh sieves, and was standby.
3, taking polyethylene glycol 442.5g after the heating in water bath fusion, is cooled to 50～55 ℃, insulation adds Fructus Evodiae extract powder, volatile oil micropowder silica gel mixture, stirs, (die throat diameter 15mm in the impouring mould, high 2.5mm), cooling, the demoulding, get tablet, tablet is put in the PVC nib of foaming, be covered with non-woven rubberized fabric, get product.
Embodiment 3:
1, get Herba Asari 290g, add 8 times of water gagings and soaked 1 hour, water vapour distillation 3 hours gets volatile oil, adds the micropowder silica gel mixing of 0.8 times of amount of volatile oil volume, crosses 100 mesh sieves, and is standby.
2, get Fructus Evodiae 870g, add 60% ethanol extraction 2 times, each 2 hours, filter while hot, decompression filtrate recycling ethanol is condensed into thick paste, and drying under reduced pressure was pulverized 100 mesh sieves, and was standby.
3, taking polyethylene glycol 287.0g after the heating in water bath fusion, is cooled to 50～55 ℃, insulation adds Fructus Evodiae extract powder, volatile oil micropowder silica gel mixture, stirs, (die throat diameter 15mm in the impouring mould, high 2.5mm), cooling, the demoulding, get tablet, tablet is put in the PVC nib of foaming, be covered with non-woven rubberized fabric, get product.
Claims (5)
1, a kind of preparation method for the treatment of the Chinese medicine medicine for external use of oral ulcer is characterized in that the step of method is as follows:
1) get Herba Asari, water vapour distillation gets volatile oil, adds the micropowder silica gel mixing of 0.5～2.5 times of amount of volatile oil volume, crosses 60～200 mesh sieves, and it is standby to make volatile oil micropowder silica gel mixture;
2), get Fructus Evodiae, add 40～90% ethanol extractions, filter while hot, decompression filtrate recycling ethanol is condensed into thick paste, drying under reduced pressure was pulverized 60～200 mesh sieves, made the Fructus Evodiae extract powder, and was standby;
3), get substrate, after the heating in water bath fusion, be cooled to 45～65 ℃, the insulation, add Fructus Evodiae extract powder, volatile oil micropowder silica gel mixture, stir, cool off the demoulding in the impouring mould, get tablet, tablet is put in the PVC nib of foaming, be covered with non-woven rubberized fabric, get product.
2, a kind of preparation method for the treatment of the Chinese medicine medicine for external use of oral ulcer according to claim 1 is characterized in that described Herba Asari: Fructus Evodiae=1～10: 1～10.
3, a kind of preparation method for the treatment of the Chinese medicine medicine for external use of oral ulcer according to claim 1 is characterized in that described Herba Asari, Fructus Evodiae weight and substrate weight ratio are 1: 0.2～1.
4, a kind of preparation method for the treatment of the Chinese medicine medicine for external use of oral ulcer according to claim 1 is characterized in that described substrate is Polyethylene Glycol.
5, a kind of preparation method for the treatment of the Chinese medicine medicine for external use of oral ulcer according to claim 1 is characterized in that the nib of described mould is diameter 13～17mm, and height is 2.0～3.5mm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100497185A CN100406038C (en) | 2006-03-06 | 2006-03-06 | Method for preparing external-use Chinese medicine for treating ulcerative stomatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100497185A CN100406038C (en) | 2006-03-06 | 2006-03-06 | Method for preparing external-use Chinese medicine for treating ulcerative stomatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1850201A true CN1850201A (en) | 2006-10-25 |
| CN100406038C CN100406038C (en) | 2008-07-30 |
Family
ID=37131713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100497185A Expired - Fee Related CN100406038C (en) | 2006-03-06 | 2006-03-06 | Method for preparing external-use Chinese medicine for treating ulcerative stomatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100406038C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488774A (en) * | 2011-12-22 | 2012-06-13 | 马贵廷 | Chinese medicinal powder for treating canker sore and preparation method thereof |
| CN112791133A (en) * | 2021-02-08 | 2021-05-14 | 复旦大学附属金山医院(上海市金山区核化伤害应急救治中心、上海市金山区眼病防治所) | Traditional Chinese medicine composition for treating chronic postoperative pain and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1104512A (en) * | 1993-12-28 | 1995-07-05 | 西南民族学院 | Medicine powder for aphtha |
-
2006
- 2006-03-06 CN CNB2006100497185A patent/CN100406038C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488774A (en) * | 2011-12-22 | 2012-06-13 | 马贵廷 | Chinese medicinal powder for treating canker sore and preparation method thereof |
| CN112791133A (en) * | 2021-02-08 | 2021-05-14 | 复旦大学附属金山医院(上海市金山区核化伤害应急救治中心、上海市金山区眼病防治所) | Traditional Chinese medicine composition for treating chronic postoperative pain and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100406038C (en) | 2008-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1308012C (en) | Chinese medicine composition for treating cerebral hemorrhage and its prepn | |
| CN103169928B (en) | Externally applied traditional Chinese medicine composition for treating dysmenorrhea, as well as preparation method and application thereof | |
| CN1947739B (en) | Traditional Chinese medicine composition for treating dermal titillation and chronic eczema and its preparation method | |
| CN103041173A (en) | Traditional Chinese medicine external preparation for curing dermatitis and eczema and preparing method thereof | |
| CN101062217A (en) | Medicine combination for treating traumatic injury and the preparing method and the function thereof | |
| CN105560331A (en) | Eczematous dermatitis prevention medicine, and preparation method and application thereof | |
| CN101912527A (en) | Medicinal preparation for curing wind chill blockage disease and preparation method thereof | |
| CN104524247B (en) | One treats migrainous medical composition and its use | |
| CN1850201A (en) | Method for preparing external-use Chinese medicine for treating ulcerative stomatitis | |
| CN1850200A (en) | Formula of external-use Chinese medicine for treating ulcerative stomatitis | |
| CN102038778A (en) | Chinese medicinal composition with effects of relaxing meridians, activating collaterals, expelling wind and removing dampness and preparation method thereof | |
| CN114010700A (en) | Preparation method and application of noninvasive dermal penetration technology transdermal absorbent containing traditional Chinese medicine effective components | |
| CN1037151C (en) | Blood pressure lowing plaster and its preparation | |
| CN1134298A (en) | "Dianxianningxiwan" pills-Chinese patent medicine for epilepsy | |
| CN112521389A (en) | Medicament and method for promoting wound healing | |
| JP5265347B2 (en) | Use of konjac and its extract in formulating pharmaceuticals for the treatment of acute and chronic bronchitis | |
| CN106728059B (en) | Medicine for treating rheumatoid arthritis and preparation method thereof | |
| CN1272047C (en) | Medicine for invigorating liver and kidney to treat dryness of large intestine and constipation | |
| CN111643606B (en) | Gel plaster for treating insomnia and preparation method thereof | |
| CN103127278B (en) | Drug compound for treatment of rahagades of hand and foot | |
| CN108434299B (en) | Pharmaceutical composition for treating scapulohumeral periarthritis and preparation method and spray thereof | |
| CN114028483B (en) | Pharmaceutical composition and preparation for treating chronic soft tissue injury | |
| CN100536824C (en) | Slim and shaping frost, and preparation method | |
| CN1785410A (en) | Preparation method of ready prepared chinese medicinal granules for treathing pains | |
| CN102247421B (en) | Chinese herbs paste for treating gastrointestinal dysfunction and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080730 Termination date: 20140306 |